Investigational Medication Sirolimus for Lymphangioleiomyomatosis (LAM) Request More Information Trial Objective The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly. Sirolimus is approved by the United States Food and Drug Administration (FDA) for the treatment of LAM. A recent trial showed that sirolimus stabilized lung function in patients with moderate and severe disease. Our researchers want to find out if giving low-dose sirolimus earlier in the course of treatment safely and effectively prevents further lung damage from LAM. Enrollment This trial is active and currently recruiting. Who Can Participate Adults who have been diagnosed with lymphangioleiomyomatosis are eligible to participate. Age: 18+ Gender: Any Gender Estimated Time Commitment 2 years The study will last for two years and involve seven visits and one phone call, as well as a remote blood draw. Total time commitment is about 9 hours. Compensation Provided Trial Contact For more information, contact: Jami Henriksen 303.398.1233 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors National Institutes of Health (NIH) Principal Investigators Gregory Downey, MD + × Gregory Downey, MD Professor Executive Vice President, Academic Affairs Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 5 out of 5 stars Make an Appoinment Request More Information First Name:* Last Name:* Email Address:* Phone:*
Trial Objective The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly. Sirolimus is approved by the United States Food and Drug Administration (FDA) for the treatment of LAM. A recent trial showed that sirolimus stabilized lung function in patients with moderate and severe disease. Our researchers want to find out if giving low-dose sirolimus earlier in the course of treatment safely and effectively prevents further lung damage from LAM.